Literature DB >> 19712040

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

Hartmut J Ehrlich1, Markus Müller, Sandor Fritsch, Markus Zeitlinger, Greg Berezuk, Alexandra Löw-Baselli, Maikel V W van der Velden, Eva Maria Pöllabauer, Friedrich Maritsch, Borislava G Pavlova, Paul A Tambyah, Helen M L Oh, Emanuele Montomoli, Otfried Kistner, P Noel Barrett.   

Abstract

Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate safety and immunogenicity. Seventy-seven of 141 subjects in this study received a booster (12-17 months after priming) with a 7.5-microg dose of a clade 2.1 A/Indonesia vaccine. The prime-boost regimen resulted in antibody responses against clade 1, 2.1, 2.2, and 2.3 viruses that were significantly higher than those after the priming regimen. These findings demonstrate that a prime-boost regimen may alleviate vaccine supply constraints in a pandemic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712040     DOI: 10.1086/605608

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion.

Authors:  Shin Murakami; Taisuke Horimoto; Mutsumi Ito; Ryo Takano; Hiroaki Katsura; Masayuki Shimojima; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

Review 2.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

3.  [On the press coverage on the Austrian allocation of vaccine against the pandemic influenza A/H1N1].

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 4.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

Authors:  Maikel V W van der Velden; Alexander Geisberger; Thomas Dvorak; Daniel Portsmouth; Richard Fritz; Brian A Crowe; Wolfgang Herr; Eva Distler; Eva M Wagner; Markus Zeitlinger; Robert Sauermann; Christoph Stephan; Hartmut J Ehrlich; P Noel Barrett; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-04-16

6.  A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Authors:  Kawsar R Talaat; Catherine J Luke; Surender Khurana; Jody Manischewitz; Lisa R King; Bridget A McMahon; Ruth A Karron; Kristen D C Lewis; Jing Qin; Dean A Follmann; Hana Golding; Kathleen M Neuzil; Kanta Subbarao
Journal:  J Infect Dis       Date:  2014-03-05       Impact factor: 5.226

7.  Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Authors:  Gerald Aichinger; Barbara Grohmann-Izay; Maikel V W van der Velden; Sandor Fritsch; Manuela Koska; Daniel Portsmouth; Mary Kate Hart; Wael El-Amin; Otfried Kistner; P Noel Barrett
Journal:  Clin Vaccine Immunol       Date:  2014-10-29

Review 8.  A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

9.  A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses.

Authors:  Fan Zhou; Guiqin Wang; Philippe Buchy; Zhipeng Cai; Honglin Chen; Zhiwei Chen; Genhong Cheng; Xiu-Feng Wan; Vincent Deubel; Paul Zhou
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

10.  A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

Authors:  Otfried Kistner; Brian A Crowe; Walter Wodal; Astrid Kerschbaum; Helga Savidis-Dacho; Nicolas Sabarth; Falko G Falkner; Ines Mayerhofer; Wolfgang Mundt; Manfred Reiter; Leopold Grillberger; Christa Tauer; Michael Graninger; Alois Sachslehner; Michael Schwendinger; Peter Brühl; Thomas R Kreil; Hartmut J Ehrlich; P Noel Barrett
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.